

ESMO Preceptorship on Lung Cancer

PROGRAMME

**ESMO
PRECEPTORSHIP**

**RABAT MOROCCO
26-27 JANUARY 2024**

Co-Chairs

Mounir Bachouchi, Morocco
Jaafar Bennouna, France
Hassan Errihani, Morocco
Céline Mascaux, France

ESMO PRECEPTORSHIP PROGRAMME

LUNG CANCER

Daily clinical practice, present and future

Rabat, Morocco
26-27 January 2024

CO-CHAIRS Mounir Bachouchi, Morocco
Jaafar Bennouna, France
Hassan Errihani, Morocco
Céline Mascaux, France

SPEAKERS Nadia Benchakroun, Morocco
Souheil Boubia, Morocco
Ibrahim El Ghissassi, Morocco
Basma El Khannoussi, Morocco
Malika Gamaz, Algeria
Cécile Le Pechoux, France
Nesrine Mejri, Tunisia
Laura Mezquita, Spain

LEARNING OBJECTIVES

- To select the best treatment in a multidisciplinary approach for early stage Non-Small Cell Lung cancer (NSCLC)
- To identify molecular alterations driving the management of metastatic NSCLC
- To learn about the best strategy for metastatic NSCLC with targetable molecular alterations
- To learn about the best strategy for metastatic NSCLC eligible for immunotherapy
- To learn about the best strategy for SCLC

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

AstraZeneca 

 **MSD**

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org

ESMO GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

Friday, 26 January 2024

09:00-09:20 20'	Opening and welcome	
10'	Welcome from ESMO and course introduction	Mounir Bachouchi, MA
10'	Overview of Lung Cancer in Morocco	Hassan Errihani, MA
09:20-10:15 55'	SESSION 1 Diagnostics for Lung Cancer	Chairs: Jaafar Bennouna, FR Hassan Errihani, MA
20'	Role of EBUS-TBNA	Souheil Boubia, MA
25'	Role of pathologist	Basma El Khannoussi, MA
10'	Q&A	All
10:15-10:45	Coffee break	
10:45-11:55 70'	SESSION 2 Radical treatment for early stage NSCLC	Chairs: Mounir Bachouchi, MA
30'	Surgery for early stage NSCLC	Souheil Boubia, MA
30'	Stereotactic ablative RT for early stage NSCLC	Nadia Benchakroun, MA
10'	Q&A	All
11:55-13:15 80'	SESSION 3 – Part I Multimodality therapy for localized NSCLC	Chairs: Hassan Errihani, MA
50'	Controversies for peri-operative treatment <ul style="list-style-type: none"> - Adjuvant treatment - Neo-adjuvant treatment 	Mounir Bachouchi, MA Jaafar Bennouna, FR
10'	Q&A	All
20'	Participants clinical case discussion (2x10')	Faculty
13:15-14:15	Lunch	
14:15-15:35 80'	SESSION 3 – Part II Multimodality therapy for localized NSCLC	Chairs: Mounir Bachouchi, MA Jaafar Bennouna, FR
30'	Chemoradiation for locally advanced NSCLC	Cécile Le Pechoux, FR
30'	Management of oligometastatic disease	Laura Mezquita, ES
10'	Q&A	All
10'	Participants clinical case discussion (1x10')	Faculty
15:35-16:05	Coffee break	

16:05-18:15 130'	SESSION 4 Advanced NSCLC	Chairs: Mounir Bachouchi, MA Hassan Errihani, MA
20'	Role of molecular biologist	Céline Mascaux, FR
20'	First-line treatment for advanced NSCLC without oncogenic addiction	Céline Mascaux, FR
20'	Second-line treatment for advanced NSCLC	Nesrine Mejri, TN
20'	Best strategy for advanced NSCLC with KRAS mutation	Laura Mezquita, ES
10'	Q&A	All
40'	Participants clinical case discussion (4x10')	Faculty
20:30	Dinner	

Saturday, 27 January 2024

09:00-10:40 100'	SESSION 5 Advanced NSCLC with oncogenic addiction	Chairs: Mounir Bachouchi, MA Céline Mascaux, FR
30'	Treatment of NSCLC with EGFR mutations	Ibrahim El Ghissassi, MA
30'	Treatment of NSCLC positive for ALK or ROS	Hassan Errihani, MA
30'	Beyond EGFR, ALK, ROS: Other molecular alterations	Jaafar Bennouna, FR
10'	Q&A	All
10:40-11:10	Coffee break	
11:10-13:10 120'	SESSION 6 Small Cell Lung Cancer	Chairs: Jaafar Bennouna, FR Hassan Errihani, MA
30'	Indications of radiotherapy in localized and advanced SCLC	Cécile Le Pechoux, FR
30'	Chemotherapy and/or immunotherapy for localized and advanced SCLC	Malika Gamaz, DZ
10'	Q&A	All
50'	Participants clinical case discussion (5x10')	Faculty
13:10-13:20 10'	Conclusion and farewell	Mounir Bachouchi, MA Jaafar Bennouna, FR Hassan Errihani, MA
13:20-14:20	Lunch	

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion